Gujarat Themis Biosyn Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-a331579cb8c55fd3a785da34.pdf

Key Takeaways


The Quarter's Noise: One-Offs Masking the Base Business

Patel: "We needed to transform ourselves from intermediate API fermentation company into a fermentation-based CDMO. And this is very important because it had to be fermentation-based. This is our DNA, this is our ethos."

The Capacity Story: Doubling Fermentation, Halving Energy Costs

Patel: "The global fermentation capacity is 1/7 of what is required over the next 3 to 4 years. ... So I think we have to do something horribly wrong not to capture this particular opportunity with the kind of capacity that we have now and with the kind of capability we have right now."

MBJ Integration: A Technology Bet Still Being Sized

Patel: "We can have a lot of ideas, we can have a lot of thoughts, but unless everyone is aligned, we cannot move ahead."

MDJ: The Margin Levers Already Visible


Sanofi: The Only Forward-Integration Path That Protects the Base

Patel: "We could not get into finished dosage forms without cannibalizing our current customers. And this is very important because this is our bread and butter. So the only portfolio that we could actually go for was a branded portfolio which was not being supplied by, or which were the markets which were not catered to by our current customers. And there is only one portfolio, that is Sanofi's portfolio."

API Forward Integration: Slow, Selective, and Margin-Protective

Patel: "We want to do APIs, we are going to do APIs but selectively, not in a way whereby we are cannibalizing our current customers. So I think there's got to be a right balance in terms of what we are doing right now and where we want to go with the APIs."

Guidance & Commitments

CommitmentSpecificsTimeline
New fermentation revenueRevenue benefits from new 990 KL capacity to begin flowingQ3 FY27 onwards
EBITDA margin recoveryGTBL EBITDA and EBITDA margin to return to original levels as new capacity revenue flows inQ3 FY27 onwards
Forex loss reversalUnrealised ~₹16 crore forex loss expected to reverse with favourable JPY movementNext quarter(s)
Hybrid power plant completionFull project (3 wind turbines) up and runningBy December
MDJ-GTBL strategic alignmentBoth companies "very well aligned" on working together; incentive model combining EBITDA and growth finalisedBy March (end of FY27)
MDJ 5-year expectationsManagement to state what it exactly expects out of MDJ over the next 5 yearsBy end of March
Sanofi transaction closeDeal closure subject to FDI clearancesJanuary–February (long-stop June)
Sanofi growth strategy disclosureGranular details to be shared in a separate meetingAfter transaction closes
NCD India partial repaymentPartial repayment through preferential issue proceeds, awaiting stock exchange approvalUndated
API forward integrationAt least half of intermediate capacity converted into APIOver next 3–4 years

Key Metrics

MetricQ2 FY27
Revenue (standalone)Almost flat, sold out on old fermentation capacity
EBITDATemporarily impacted, operating expenses of new fermentation facility hit P&L; revenue benefits expected from Q4 FY27
EBITDA marginExpected to come back to original levels once new facility revenue flows in from Q4 FY27
PATDown, due to temporary acquisition-related financing costs
Consolidated unrealized forex loss~₹16 cr, non-cash accounting adjustment expected to reverse with favorable currency fluctuations
MBJ consolidation period13 days only (ownership transferred 18th September); major September revenue booked in first 17 days, resulting in MBJ P&L loss for the period
Exceptional expenses₹1.2 cr, earthquake in Japan in July end impacted one MBJ plant
GTBL fermentation capacity990 kiloliters total, doubled from 450 KL; new facility started operating from September 26
Hybrid power plant18.45 MW (9 MW solar, 9.9 MW wind); Phase 1 commissioned 9th October; full project by December; energy cost expected to reduce to half
MBJ turnover (annual)Close to about ₹550 cr
MBJ EBITDA margin (FY26)25%, improved from 20% in FY24
MBJ acquisition purchase consideration₹1,351 cr, covering 100% equity buyout, stock option rights, and employee bonuses
MBJ existing loans refinanced~₹632 cr, funded via Singapore NCD of ₹43 cr and ₹189 cr from MBJ's own books
MBJ capacity utilizationEach block at about 20–30%, some even lower
MBJ new project EBITDA marginOver 35%
Sanofi portfolio revenue (annual)About €62 million
Sanofi portfolio gross margin55–58% currently; expected to reach 74–75% after API integration in 3 years
Sanofi portfolio historical growth5–6% CAGR over last 5 years
Mezzanine financing cost16–17% currently; expected to come down to about 9% after refinancing, with Japan rate possibly 4% or less
GTBL free cash flow expectationAround ₹15–20 cr
MBJ free cash flow expectationEasily around ₹90–100 cr (combined entity, excluding acquisitions and incremental capex)